Quantitative analysis described no significant difference in the CXCR4 PET signal between PD-L1 inhibitor and isotype Ctrl after the treatment phase (day 15) or following the recovery phase (49 days after tumor induction, 42 days after starting anti-PD-L1 or isotype Ctrl treatment) (Figure 5C). This evidence concerns the gene CXCR4 and neoplasm.